ICHG 2024

ICHG 2024 was a huge success! Attendees can request CEs (AMA, ANCC, and CDR credits) and provide feedback here.

Bringing together the world’s leading researchers in hyperemesis gravidarum, this two-day event at the Crowne Plaza Ventura Beach Hotel will be an excellent opportunity for delegates to hear about the latest research developments and innovative treatments for this complex condition. Charities and patients will have opportunities to engage as well. Read the prospectus to learn more.

Plan your attendance

Thank-you to everyone who attended!

Volunteer

Thank-you to all our volunteers who made ICHG 2024 a huge success!

Get Involved

Grants

National Institute of Child Health and Human Development (NICHD)

Gold Sponsors

Friend sponsors

Media Partner

Share the Facts About HG

HG, hyperemesis gravidarum, is a pregnancy disease marked by weight loss, malnutrition, and dehydration due to severe nausea and/or vomiting.
HG is not the “morning sickness” of healthy, normal pregnancies. It is a distinct diagnosis marked by severe and relentless symptoms that pose significant risks to the health of both mom and baby. Over 1/3rd of HG babies do not make it to term.
HG babies are at increased risk for low birth weight, small size for gestational age, and preterm birth. In utero exposure to HG is linked to a 3.6-fold increased risk of emotional/behavioral & developmental disorders, and autism. Up to 15% of HG pregnancies end due to therapeutic terminations, citing “no hope for relief.” Current treatments are not always adequate to prevent termination of these wanted pregnancies.
Mothers with more severe HG can experience pneumothorax, organ rupture, retinal detachment and blindness, eardrum and jaw damage, rib fractures, esophageal tears, the neurological syndrome Wernicke’s encephalopathy, or even death.
18% of women report full criteria of post-traumatic stress syndrome (PTSS) following an HG pregnancy. More than half of mothers have post-traumatic stress symptoms.
In 2016, the nearly 400,000 emergency and inpatient visits for HG in the U.S. cost more than $3,000,000,000. Outpatient treatment, medications, and nutritional therapy were additional.
HG is the leading cause of hospitalization in early pregnancy, and is second only to preterm labor as the most common overall cause of hospitalization during pregnancy.